CSIMarket


Alimera Sciences Inc   (ALIM)
Other Ticker:  
 


 

Alimera Sciences Inc

ALIM's Financial Statements and Analysis



Alimera Sciences Inc narrowed forth quarter of 2023 net loss per share of $-0.05 compare to net loss per share of $-0.53 recorded in the same quarter a year ago and improved compare to net loss per share of $-0.06 realized in previous quarter.


forth quarter of 2023
Earnings Per Share Revenues
$ -0.05 $  27 Mill
$+0.48     $+13M     +89.98 %



Alimera Sciences Inc 's Revenue rose by 89.98 % in forth quarter of 2023 (Dec 31 2023) year on year, to $27 million and advanced by 17.9 % sequentially.


Alimera Sciences Inc is Expected to report next financial results on March 30, 2024.

More on ALIM's Income Statement



Alimera Sciences Inc 's in theforth quarter of 2023 recorded net loss of $-3.781 million, an increase from net loss of $-3.780 million in IV. Quarter a year ago.

Sequentially net loss advanced

More on ALIM's Growth

Alimera Sciences Inc Inventories
Inventories grew by 17.07 % to $2 million from IV. Quarter a year ago, sequentially inventories rose by 6.76 %. ALIM's Cash flow In the forth quarter of 2023 company's net cash flow was $4 million, capital expenditures fell by -0.0841.19%, to $0 millions compare to same quarter a year ago

More on ALIM's Cash flow Statement


Alimera Sciences Inc does not pay out common stock dividend.

In trailing twelve-month period Alimera Sciences Inc payed $ -0.56 cash per share, on a free-cash flow basis .

Book value grew by 19.18 % sequentially to $1.81 per share.
Tangible Book value fell to $ -2.01 per share from $ -1.65.

Company repurchased 6.64 million shares or 20.68 % in Dec 31 2023.


More on ALIM's Dividends

 Market Capitalization (Millions) 99
 Shares Outstanding (Millions) 25
 Total Debt (Millions $) 64
 Revenue (TTM) (Millions $) 80
 Net Income (TTM) (Millions $) -20
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) -76
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Alimera Sciences Inc does not pay out common stock dividend.

In trailing twelve-month period Alimera Sciences Inc had negative $ -0.56 cash flow per share, on a free-cash flow basis .

Book value grew by 19.18 % sequentially to $1.81 per share.
Tangible Book value fell to $ -2.01 per share from $ -1.65.

Company repurchased 6.64 million shares or 20.68 % in Dec 31 2023.


More on ALIM's Balance Sheets

 Market Capitalization (Millions) 99
 Shares Outstanding (Millions) 25
 Total Debt (Millions $) 64
 Revenue (TTM) (Millions $) 80
 Net Income (TTM) (Millions $) -20
 Cash Flow (TTM) (Millions $) 7
 Capital Exp. (TTM) (Millions $) -76
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   


  News about Alimera Sciences Inc Earnings

Alimera Sciences Inc. Achieves Remarkable Growth with 89.978% Increase in Revenue

Alimera Sciences Inc, a leading pharmaceutical company specializing in ophthalmic solutions, has shown significant improvement in its most recent fiscal period. The company reported an impressive 89.978% increase in revenue, reaching $26.65 million, which has contributed to cutting losses to $-0.05 per share from $-0.53 in the same quarter a year prior. This substantial growth in revenue is a testament to the company's strategic initiatives and focus on driving top-line growth.
In contrast to the third quarter, revenue improved by 17.898% from $22.61 million, with earnings per share also showing improvement. The company's net deficit for the fourth quarter of 2023 stood at $-3.781 million, slightly highe...

Alimera Sciences Inc Achieves Impressive Revenue Surge, Addressing Fiscal Shortfall in 2023

Alimera Sciences Inc Sees Decent Revenue Growth in Third Quarter, Signals Positive Future Performance
November 13, 2023
Alimera Sciences Inc, a leading player in the Major Pharmaceutical Preparations industry, reported a significant increase in revenue for its most recent fiscal period, signaling positive prospects for the company's future. The company's revenue grew by an impressive 66.245% to reach $22.61 million, contributing to a significant reduction in losses from $-0.75 per share in the comparable reporting season a year ago to $-0.06 per share.
Compared to its major competitors in the Major Pharmaceutical Preparations sector, Alimera Sciences Inc's revenue growth outpaced the industry ave...

Alimera Sciences Inc Delivers Stunning Double-Digit Revenue Growth in Latest Fiscal Results, Smashing Expectations

/>Alimera Sciences Inc., a company operating in the Major Pharmaceutical Preparations sector, recently released its financial results for the April to June 30, 2023 time frame. While the company experienced significant growth in revenue, it recorded an increased deficit per share compared to the previous year. This article will outline the key facts from the financial report and provide insight into the current performance and prospects of Alimera Sciences Inc.
Key Points:
1. Deficit per Share:
- Alimera Sciences Inc.'s deficit per share increased to $-1.32 in Q2 2023 from $-0.45 in the previous year.
- This growth in deficit per share reflects a widening loss for the company, indicatin...

In an impressive surge, Alimera Sciences Inc witnesses a remarkable 13.851% revenue growth during the first quarter of the 2023 earnings season

Alimera Sciences Inc, a pharmaceutical company specializing in treating eye diseases, has reported mixed financial results for the first quarter of the 2023 earnings season. While the company's revenue increased significantly by 13.851% to $13.55 million from the corresponding financial reporting period a year ago, it recorded a net shortfall of $-4.968 million, resulting in a deficit of $-0.71 per share.
Comparing the recent numbers with the prior financial reporting period, the company's revenue decreased by -3.443% from $14.03 million, while the net shortfall increased from $-0.53 per share. It is worth noting that the current net shortfall is lower than the corresponding figure of $-5.955 million a y...


Date modified: 2024-03-10T16:59:30+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com